Quidel Partners With San Diego Padres Organization for COVID-19 Testing
April 01 2021 - 7:30PM
Business Wire
Frequent COVID-19 Testing Program Keeps Padres
Front Office Team and Petco Park Staff Feeling “Safe At Home”
Quidel Named “Official Diagnostics Partner” for
the MLB Franchise
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading
provider of rapid diagnostic testing solutions, cellular-based
virology assays and molecular diagnostic systems, announced today
that after several months supporting the Padres Front Office’s
efforts to reopen safely, Quidel has been chosen as “Official
Diagnostics Partner” of the San Diego Padres Major League Baseball
(MLB) franchise. The company will be providing excellent performing
Sofia® 2 instruments and Sofia® SARS Antigen tests for use by the
Padres medical staff for the Front Office Team, Event Staff and our
Petco Park partners including Aramark, DNC, Elite and others.
“Our partnership with Quidel has been critical to enabling
today’s Opening Day at Petco Park and helping bring the excitement
of Major League Baseball back to Padres fans,” said Padres Chief
Executive Officer Erik Greupner. “Quidel’s rapid antigen
COVID-19 tests provide results in just 15 minutes, giving our
Padres staff and Petco Park partners the confidence to feel ‘Safe
At Home’ at our ballpark.”
“The Quidel Team has been at the forefront of the fight against
the COVID-19 pandemic since the start and was the first to
introduce rapid antigen tests to empower providers with a rapid
solution for COVID-19 diagnosis and helping to limit the spread of
COVID-19 in our community,” said Douglas Bryant, president and
CEO of Quidel Corporation. “San Diego is our home, and it gives
our people tremendous pride to be the Official Diagnostics Partner
of the Padres and to help ensure the entire Petco Park Team is
‘Safe At Home.’ Go Padres!”
Headquartered in San Diego, Quidel is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s
comprehensive product portfolio includes tests for a wide range of
infectious diseases, cardiac and autoimmune biomarkers, as well as
a host of products to detect COVID-19. With products made in
America, Quidel’s mission is to provide patients with immediate and
frequent access to highly accurate, affordable testing for the good
of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
About the Sofia 2 SARS Antigen FIA Test
The Sofia SARS Antigen FIA has not been FDA cleared or approved,
but has been authorized by the FDA under an Emergency Use
Authorization (EUA) for use by authorized laboratories for the
detection of proteins from SARS-CoV-2, not for any other viruses or
pathogens. No CLIA Waiver will be required for organizations
administering the test. This assay is only authorized for the
duration of the declaration that circumstances exist justifying the
authorization of emergency use of in vitro diagnostics for
detection and/or diagnosis of COVID-19 under Section 564(b)(1) of
the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §
360bbb-3(b)(1), unless authorization is terminated or revoked
sooner.
View our story told by our people at
www.quidel.com/ourstory.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the federal
securities laws that involve material risks, assumptions and
uncertainties. Many possible events or factors could affect our
future results and performance, such that our actual results and
performance may differ materially from those that may be described
or implied in the forward-looking statements. As such, no
forward-looking statement can be guaranteed. Differences in actual
results and performance may arise as a result of a number of
factors including, without limitation: the impact and duration of
the COVID-19 global pandemic; competition from other providers of
diagnostic products; our ability to accurately forecast demand for
our products and products in development, including in new market
segments; our ability to develop new technologies, products and
markets and to commercialize new products; our reliance on sales of
our COVID-19 and influenza diagnostic tests; our reliance on a
limited number of key distributors; quantity of our product in our
distributors’ inventory or distribution channels; changes in the
buying patterns of our distributors; the financial soundness of our
customers and suppliers; lower than anticipated market penetration
of our products; third-party reimbursement policies and potential
cost constraints; our ability to meet demand for our products;
interruptions, delays or shortages in the supply of raw materials,
components and other products and services; failures in our
information technology and storage systems; our exposure to data
corruption, cyber-based attacks, security breaches and privacy
violations; international risks, including but not limited to,
economic, political and regulatory risks; continuing worldwide
political and social uncertainty; our development, acquisition and
protection of proprietary technology rights; intellectual property
risks, including but not limited to, infringement litigation; the
loss of Emergency Use Authorizations for our COVID-19 products and
failures or delays in receipt of reviews or regulatory approvals,
clearances or authorizations for new products or related to
currently-marketed products by the U.S. Food and Drug
Administration (the “FDA”) or other regulatory authorities or loss
of any previously received regulatory approvals, clearances or
authorizations or other adverse actions by regulatory authorities;
our contracts with government entities involve future funding,
compliance and possible sanctions risks; product defects; changes
in government policies and regulations and compliance risks related
thereto; our ability to manage our growth strategy and successfully
identify, acquire and integrate potential acquisition targets or
technologies and our ability to obtain financing; our acquisition
of Alere’s Triage® business presents certain risks to our business
and operations; the level of our deferred payment obligations; our
exposure to claims and litigation that could result in significant
expenses and could ultimately result in an unfavorable outcome for
us, including the ongoing litigation between us and Beckman
Coulter, Inc.; we may need to raise additional funds to finance our
future capital or operating needs; our debt, deferred and
contingent payment obligations; competition for and loss of
management and key personnel; business risks not covered by
insurance; changes in tax rates and exposure to additional tax
liabilities or assessments; and provisions in our charter documents
and Delaware law that might delay or impede stockholder actions
with respect to business combinations or similar transactions.
Forward-looking statements typically are identified by the use of
terms such as “may,” “will,” “should,” “might,” “expect,”
“anticipate,” “estimate,” “plan,” “intend,” “goal,” “project,”
“strategy,” “future,” and similar words, although some
forward-looking statements are expressed differently. The risks
described in reports and registration statements that we file with
the Securities and Exchange Commission from time to time, should be
carefully considered, including those discussed in Item 1A, “Risk
Factors” and elsewhere in our Annual Report on Form 10 K for the
year ended December 31, 2020 and in our subsequent Quarterly
Reports on Form 10 Q. You are cautioned not to place undue reliance
on these forward-looking statements, which reflect management’s
analysis only as of the date of this press release. Except as
required by law, we undertake no obligation to publicly release any
revision or update of these forward-looking statements, whether as
a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210401005961/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931 Investors Contact: Quidel Corporation Ruben
Argueta (858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2024 to Jun 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2023 to Jun 2024